Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Synageva BioPharma Corp (NASDAQ: GEVA) acted responsibly on behalf of investors’ profitability in the planned $8.4 billion sale to Alexion Pharmaceuticals Inc (NASDAQ: ALXN).

On May 7, 2015, Synageva BioPharma Corp (NASDAQ: GEVA) and Alexion Pharmaceuticals Inc (NASDAQ: ALXN) announced that they had entered into a merger agreement.

Under the terms of the merger agreement, Alexion Pharmacueticals Inc, will acquire all outstanding shares of Synageva BioPharma Corp common stock for $115 in cash and 0.6581 Alexion shares per Synageva share. This gives Synageva shares a total value of $226.

Based in Cheshire, CT, and founded in 1992, Synageva BioPharma Corp is a biopharmaceutical company that develops and markets therapeutic products for patients with severe and life-threatening rare diseases. One of its flagship therapies is Soliris, a treatment for patients with paroxysmal nocturnal hemoglobinuria and a treatment for patients with atypical hemolytic uremic syndrome.

The investigation is looking to uncover whether Synageva BioPharma Corp was undervalued at the cost of the shareholders considering one analyst’s opinion of their stock is valued at $230.00 per share.

If you purchased Synageva BioPharma Corp (NASDAQ: GEVA)  prior to May 7, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185